Paskowitz & Associates has filed a class action lawsuit on December 2, 2004 in the United States District Court for the Southern District of New York on behalf of all purchasers who, on December 1, 2004, purchased GeoPharma, Inc. (NasdaqSC--GORX) securities. The lawsuit was filed against GeoPharma, Inc. ("GeoPharma" or "the Company), and its President, Kotha Sekharam.

For further information you may call toll free, 800-705-9529, or contact Paskowitz & Associates by e-mail by writing to classattorney@aol.com.

The action arises out representations that GeoPharma, a pharmaceuticals company, was engaged in the development of a "patent-pending" drug for the treatment of oral inflammation suffered by cancer patients known as mucositis. The product was dubbed Mucotrol (TM). On December 1, 2004, GeoPharma announced that Mucotrol had been approved by the FDA. On this news, GeoPharma shares shot up on heavy volume, reaching $11.25 per share. Shortly thereafter, however, investigative journalists uncovered that the FDA had not approved any such drug. It was then conceded by the Company that Mucotrol was a "device", not a drug. This is a material difference. Nor was it the case that Mucotrol contained any medicinal ingredients at all. GeoPharm's sales projections were also called into question. On these revelations, GeoPharma shares sharply declined, last trading at $6.81 per share on December 1, 2004 at which point trading was halted.

If you purchased GeoPharma securities on December 1, 2004, you may qualify to serve as Lead Plaintiff on behalf of the Class, which consists of all persons and entities who purchased GeoPharma securities on December 1, 2004 (the "Class"). You are not required to have sold your GeoPharma securities in order to claim damages, or to serve in this role. All motions for appointment as Lead Plaintiff must be filed with the Court no later than January 31, 2005.